Home›Stocks›LFST

LFST — structural market context

LifeStance Health Group, Inc.

Structural market context from public regulatory and market data, shown with its as-of dates. Descriptive only: nothing on this page is a recommendation, a prediction, or advice to buy or sell any security.

What changed

As of the close on Oct 16. Each line shows the earlier value, the later value and their dates.

Price

Close $11.74 (Oct 16) vs $12.37 (Oct 15): −5.09%.

Volume

0.65× its 20-session average (4.3M) on Oct 16.

Includes pre- and post-market trading.

Short interest

Short interest 15.5M shares (settlement Sep 30) vs 16.3M (Sep 15).

No new publication in this window. Latest: settlement Sep 30, published Oct 10.

Fails-to-deliver

Latest file (settlements Sep 15–Sep 30, published Oct 16): 1 day with fails, largest 167K shares on Sep 16.

Previous file (settlements Sep 1–Sep 14, published Sep 30): 2 days with fails, largest 130K shares on Sep 10.

Analyst rating actions

None recorded in this window.

Insider filings (Form 4)

None recorded in this window.

LFST short interest & days to cover

SHARES SHORT
15.5M
% OF FLOAT
—
DAYS TO COVER
2.5
CHANGE VS PRIOR
-4.6%

FINRA consolidated short interest, reported twice a month and published ~2 weeks after each settlement date. % of float uses reported free float. · as of 2026-09-30 (16d ago)

LFST fails-to-deliver (FTD)

Settlement dateFailed sharesPrice
2026-09-16 · 30d167K$13.06
2026-09-10 · 36d130K$12.62
2026-09-02 · 44d14$12.6

SEC fails-to-deliver files, published twice a month with ~6 weeks of delay.

LFST insider buying and selling (Form 4)

Last 12 months, Form 4 codes P and S: 0 purchases · 4 sales

InsiderTypeSharesValueFiled
TPG GP A, LLC · 10 percent ownerSell (S)18.4M$226.3M2026-09-15
Paunovich Vukasin · officer: Chief Technology OfficerSell (S)42K$541K2026-09-04
DeLuca Teresa · directorSell (S)8K$95K2026-08-18
DeLuca Teresa · directorSell (S)20K$250K2026-08-14

SEC Form 4 filings: purchases and sales reported on Form 4 (transaction codes P and S) only; grants and option exercises excluded. Attributed public records.

LFST analyst ratings

FirmActionRatingPublished
KeyBancholdOverweight2026-10-05
KeyBancprice_target—2026-10-05
BarclaysholdOverweight2026-09-10
Barclaysprice_target—2026-09-10
Canaccord Genuityprice_target—2026-09-09

Rating actions as published by the firms, from public feeds. They are not graded here.

Frequently asked questions

Are insiders buying LFST?
In the last 12 months of SEC Form 4 filings, LFST recorded 0 insider purchases and 4 sales reported on Form 4 (transaction codes P and S; grants and option exercises excluded). These are attributed public records — information, not instruction.
What do analysts say about LFST?
The most recent action: KeyBanc hold to Overweight on 2026-10-05. Rating actions are shown as published by the firms; they are not graded here.
Is this page telling me to buy or sell LFST?
No. Everything on this page is descriptive, structural market context from public data, shown with its as-of dates. TradeAI News does not issue directional recommendations, price predictions, or buy/sell advice — for any ticker.
All covered stocksShort Interest & FTD trackerInsider Buying trackerThe platform

More tickers starting with L

LEGN · Legend Biotech Corporation AmeLILA · Liberty Latin America Ltd. ClaLIN · Linde plcLITE · Lumentum Holdings Inc. CommonLPA · Logistic Properties of the AmeLPSN · LivePerson, Inc.All L →

This is the teaser.

Latest rows shown. Full history, market-wide screens, cluster detection and the context journal live in the dashboard.

Start free →View plans →

Not financial advice. Trading involves risk. Descriptive structural context, never a recommendation.